A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects

References

• Manion J, Waller MA, Clark T, Massingham JN, Neely GG. Developing modern pain therapies. Front Neurosci. 2019;13:1370. doi:10.3389/fnins.2019.01370
   PubMed Web of Science ®Google Scholar
• Ducharme J. Acute pain and pain control: state of the art. Ann Emerg Med. 2000;35(6):592–603. doi:10.1016/S0196-0644(00)70033-3
   PubMed Web of Science ®Google Scholar
• Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol. 1996;35(Suppl 1):4–12. doi:10.1093/rheumatology/35.suppl_1.4
   PubMedGoogle Scholar
• Ahmed M, Khanna D, Furst DE. Meloxicam in rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2005;1(4):739–751. doi:10.1517/17425255.1.4.739
   PubMedGoogle Scholar
• Hasan SM, Shoaib MH, Hassan F, Rehman IU. Bioequivalence studies of two brands of meloxicam tablets in healthy Pakistani volunteers. Pak J Pharm Sci. 2009;22(2):199–204.
   PubMed Web of Science ®Google Scholar
• Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung. 1997;47(3):253–258.
   PubMed Web of Science ®Google Scholar
• Turck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996;35(Suppl 1):13–16. doi:10.1093/rheumatology/35.suppl_1.13
   PubMedGoogle Scholar
• Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajko R, Szabo-Revesz P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm. 2009;381(2):153–159. doi:10.1016/j.ijpharm.2009.07.009
   PubMedGoogle Scholar
• Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl 1):68–77. doi:10.1093/rheumatology/35.suppl_1.68
   PubMedGoogle Scholar
• Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol. 1995;48(3–4):269–272. doi:10.1007/BF00198310
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Y, Wu Y, et al. Pharmacokinetics of meloxicam tablets in healthy Chinese adults in the fasting and fed states: a single-site, single-dose, randomized, open, 2-period, 2-sequence, crossover bioequivalence study. Clin Pharmacol Drug Dev. 2022;11(1):71–79. doi:10.1002/cpdd.965
   PubMed Web of Science ®Google Scholar
• Gupta A, Bah M. NSAIDs in the treatment of postoperative pain. Curr Pain Headache Rep. 2016;20(11):62. doi:10.1007/s11916-016-0591-7
   PubMed Web of Science ®Google Scholar
• Gottlieb IJ, Tunick DR, Mack RJ, et al. Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy. J Pain Res. 2018;11:383–393. doi:10.2147/JPR.S149879
   PubMed Web of Science ®Google Scholar
• Christensen SE, Cooper SA, Mack RJ, McCallum SW, Du W, Freyer A. A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery. J Clin Pharmacol. 2018;58(5):593–605. doi:10.1002/jcph.1058
   PubMed Web of Science ®Google Scholar
• Singla N, Bindewald M, Singla S, et al. Efficacy and safety of intravenous meloxicam in subjects with moderate-to-severe pain following abdominoplasty. Plast Reconstr Surg Glob Open. 2018;6(6):e1846. doi:10.1097/GOX.0000000000001846
   PubMedGoogle Scholar
• Li J, Wang Z, Zhang H, Gao J, Zheng A. Progress in the development of stabilization strategies for nanocrystal preparations. Drug Deliv. 2021;28(1):19–36. doi:10.1080/10717544.2020.1856224
   PubMed Web of Science ®Google Scholar
• Hasunuma T, Tohkin M, Kaniwa N, et al. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol. 2016;81(6):1078–1090. doi:10.1111/bcp.12884
   PubMed Web of Science ®Google Scholar
• White PF. What are the advantages of non-opioid analgesic techniques in the management of acute and chronic pain? Expert Opin Pharmacother. 2017;18(4):329–333. doi:10.1080/14656566.2017.1289176
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–S120. doi:10.36076/ppj.2008/11/S105
   PubMed Web of Science ®Google Scholar
• Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16(7–8):354–360. doi:10.1016/j.drudis.2010.02.009
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796. doi:10.1038/nrd1494
   PubMed Web of Science ®Google Scholar
• Ochi M, Kawachi T, Toita E, et al. Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors. Int J Pharm. 2014;474(1–2):151–156. doi:10.1016/j.ijpharm.2014.08.022
   PubMedGoogle Scholar
• Mack R, Freyer A, Du W. (409) An evaluation of the efficacy and safety of N1539, a novel intra venous formulation of NanoCrystal Meloxicam, in subjects with moderate to severe pain following hysterectomy. J Pain. 2016;17(4):S77. doi:10.1016/j.jpain.2016.01.386
   Web of Science ®Google Scholar
• Clinical pharmacology review; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210583Orig1s000ClinPharmR.pdf. Accessed July 31, 2023.
   Google Scholar
• Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9–54. doi:10.2133/dmpk.DMPK-11-RV-111
   PubMed Web of Science ®Google Scholar
• Rugstad HE, Hundal O, Holme I, Herland OB, Husby G, Giercksky KE. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin Rheumatol. 1986;5(3):389–398. doi:10.1007/BF02054259
   PubMed Web of Science ®Google Scholar
• Magallanes L, Lorier M, Ibarra M, Guevara N, Vazquez M, Fagiolino P. Sex and food influence on intestinal absorption of ketoprofen gastroresistant formulation. Clin Pharmacol Drug Dev. 2016;5(3):196–200. doi:10.1002/cpdd.208
   PubMed Web of Science ®Google Scholar
• Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–157. doi:10.2165/00003088-200948030-00001
   PubMed Web of Science ®Google Scholar
• Farkouh A, Baumgartel C, Gottardi R, Hemetsberger M, Czejka M, Kautzky-Willer A. Sex-related differences in drugs with anti-inflammatory properties. J Clin Med. 2021;10(7):1441. doi:10.3390/jcm10071441
   PubMed Web of Science ®Google Scholar
• Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39(9):801–821. doi:10.1007/s40264-016-0427-8
   PubMed Web of Science ®Google Scholar
• Monteiro C, Silvestre S, Duarte AP, Alves G. Safety of non-steroidal anti-inflammatory drugs in the elderly: an analysis of published literature and reports sent to the Portuguese pharmacovigilance system. Int J Environ Res Public Health. 2022;19(6):3541. doi:10.3390/ijerph19063541
   PubMed Web of Science ®Google Scholar
• Suo Z, Sun Q, Peng X, et al. Lentinan as a natural stabilizer with bioactivities for preparation of drug-drug nanosuspensions. Int J Biol Macromol. 2021;184:101–108. doi:10.1016/j.ijbiomac.2021.06.056
   PubMed Web of Science ®Google Scholar